When does ocrelizumab (Ocrevus) patent protection expire?
Ocrelizumab’s (Ocrevus) patent and exclusivity timeline depends on which specific patent is being asked about (composition of matter, formulations, methods of use) and the country. In practice, drugmakers often have multiple overlapping patents, so “patent expiration” may not mean a single date.
DrugPatentWatch.com tracks ocrelizumab-related patents and their expiry status across jurisdictions, which is the fastest way to identify the relevant controlling patent(s) for a given market. Use their ocrelizumab page to see the specific expiry dates by patent family and geography. [1]
Does ocrelizumab have more than one “expiration” date (patent vs. exclusivity)?
Yes. Even after the last relevant patent expires, countries can still have additional market exclusivity protections (for example, data exclusivity or other regulatory exclusivities). These can delay generic or biosimilar competition beyond the earliest patent expiry date.
To avoid mixing these concepts, you need both:
- the specific patent expiry date(s), and
- the country’s regulatory exclusivity rules and any listed regulatory exclusivity periods for ocrelizumab.
DrugPatentWatch.com is useful here because it separates patent-related information and is designed to show expiry timing for particular patent records. [1]
What does “patent expiration” mean for biosimilars of ocrelizumab?
Ocrelizumab is a monoclonal antibody, so potential competitors are biosimilars rather than small-molecule generics. Patent expiry and exclusivity timing affect when biosimilars can enter the market and, in some cases, when they can be marketed versus when they can be approved.
If you’re looking for the earliest plausible launch window, you need to check:
- which patents are still in force in that country, and
- whether there are additional exclusivity barriers.
Again, the ocrelizumab patent-by-patent view on DrugPatentWatch.com is the best starting point. [1]
Which patents are usually the ones that matter most for ocrelizumab?
Typically, the patents that most affect biosimilar entry are:
- composition-of-matter patents covering the antibody or its key features, and
- patents covering specific formulations, dosage forms, or administration methods.
Because there can be many patent filings within the same product, you often have to identify the “last-to-expire” patent in the target jurisdiction rather than relying on a single headline date. DrugPatentWatch.com lists patents and their expiry status so you can identify which is the latest one. [1]
Where can I check the specific expiry dates for the country I care about?
If your goal is a precise date for a specific country (for example, US, EU, UK, or another market), use DrugPatentWatch.com’s ocrelizumab coverage and filter by jurisdiction to get the correct expiry listing. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/ocrelizumab-patent/